ChemoCentryx Inc (NASDAQ:CCXI)’s share price was up 1% during trading on Monday after the company announced better than expected quarterly earnings. The company traded as high as $12.75 and last traded at $12.07. Approximately 572,110 shares traded hands during mid-day trading, an increase of 108% from the average daily volume of 275,499 shares. The stock had previously closed at $12.19.
The biopharmaceutical company reported $0.80 EPS for the quarter, topping the consensus estimate of ($0.22) by $1.02. The company had revenue of $56.30 million for the quarter, compared to analyst estimates of $9.03 million.
Several analysts recently commented on CCXI shares. BidaskClub upgraded shares of ChemoCentryx from a “strong sell” rating to a “sell” rating in a report on Saturday, March 3rd. JPMorgan Chase & Co. raised their price target on shares of ChemoCentryx from $13.00 to $16.00 and gave the stock an “overweight” rating in a report on Tuesday. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $12.13.
The stock has a market cap of $623.73, a price-to-earnings ratio of 36.54 and a beta of 1.89.
TRADEMARK VIOLATION NOTICE: This article was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3260417/chemocentryx-ccxi-shares-up-1-following-strong-earnings.html.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.